Clinical Trials Directory

Trials / Completed

CompletedNCT05921591

Safety, Tolerability, and Pharmacokinetics of IRL201104 in Healthy Volunteers

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of IRL201104 in Healthy Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
24 (actual)
Sponsor
Revolo Biotherapeutics · Industry
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

The purpose of this clinical study is to assess the safety, tolerability and pharmacokinetics of repeat doses of IRL201104 given to healthy volunteers.

Conditions

Interventions

TypeNameDescription
DRUGIRL201104Lyophilised powder for reconstitution for IV dosing
DRUGPlaceboMatching placebo for IRL201104

Timeline

Start date
2023-05-26
Primary completion
2023-09-12
Completion
2023-09-12
First posted
2023-06-27
Last updated
2023-09-28

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT05921591. Inclusion in this directory is not an endorsement.

Safety, Tolerability, and Pharmacokinetics of IRL201104 in Healthy Volunteers (NCT05921591) · Clinical Trials Directory